Jason K Sa

List of Publications by Year
in descending order

46 papers	2,204 citations	361296 20 h-index	243529 44 g-index
50 all docs	50 docs citations	50 times ranked	4092 citing authors

#	Article	IF	Citations
1	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	13.7	320
2	Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell, 2018, 175, 1665-1678.e18.	13.5	250
3	Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nature Genetics, 2017, 49, 594-599.	9.4	223
4	Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics, 2018, 50, 1399-1411.	9.4	145
5	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018, 20, 873-884.	0.6	119
6	MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Nature Communications, 2020, 11, 3883.	5.8	110
7	Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instabilityâ€“High Gastric Cancer. Cancer Discovery, 2021, 11, 2168-2185.	7.7	105
8	A tension-mediated glycocalyxâ€“integrin feedback loop promotes mesenchymal-like glioblastoma. Nature Cell Biology, 2018, 20, 1203-1214.	4.6	103
9	ARS2/MAGL signaling in glioblastoma stem cells promotes self-renewal and M2-like polarization of tumor-associated macrophages. Nature Communications, 2020, 11, 2978.	5.8	78
10	Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biology, 2020, 21, 216.	3.8	73
11	Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPÎ² Signaling. Cancer Research, 2017, 77, 4973-4984.	0.4	68
12	Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial. Genome Medicine, 2022, 14, 1.	3.6	68
13	The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. Communications Biology, 2019, 2, 135.	2.0	49
14	Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. Nature Communications, 2020, 11, 3288.	5.8	44
15	Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy. Oncotarget, 2016, 7, 29400-29411.	0.8	30
16	Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. Neuro-Oncology, 2019, 21, 47-58.	0.6	28
17	PIP4K2A as a negative regulator of PI3K in PTEN-deficient glioblastoma. Journal of Experimental Medicine, 2019, 216, 1120-1134.	4.2	27
18	A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma HarboringHRASMutations. Clinical Cancer Research, 2020, 26, 5113-5119.	3.2	27

#	Article	IF	Citations
19	Ly6G+ inflammatory cells enable the conversion of cancer cells to cancer stem cells in an irradiated glioblastoma model. Cell Death and Differentiation, 2019, 26, 2139-2156.	5.0	25
20	In vivoRNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. Oncotarget, 2015, 6, 20145-20159.	0.8	23
21	Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth. Cancer Research and Treatment, 2018, 50, 1009-1022.	1.3	21
22	Comprehensive pharmacogenomic characterization of gastric cancer. Genome Medicine, 2020, 12, 17.	3.6	20
23	Genomic Landscape and Clinical Utility in Korean Advanced Pan-Cancer Patients from Prospective Clinical Sequencing: K-MASTER Program. Cancer Discovery, 2022, 12, 938-948.	7.7	19
24	Multi-Habitat Radiomics Unravels Distinct Phenotypic Subtypes of Glioblastoma with Clinical and Genomic Significance. Cancers, 2020, 12, 1707.	1.7	18
25	Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial. Genome Medicine, 2021, 13, 11.	3.6	17
26	Genomic and transcriptomic characterization of skull base chordoma. Oncotarget, 2017, 8, 1321-1328.	0.8	17
27	Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biology, 2019, 20, 253.	3.8	16
28	Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. International Journal of Cancer, 2019, 144, 3023-3030.	2.3	16
29	Modulation of Nogo receptor 1 expression orchestrates myelin-associated infiltration of glioblastoma. Brain, 2021, 144, 636-654.	3.7	16
30	Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma. Cell Death and Disease, 2021, 12, 374.	2.7	15
31	Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. Medical Oncology, 2018, 35, 60.	1.2	14
32	Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas. Cancer Research and Treatment, 2020, 52, 41-50.	1.3	14
33	Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. International Journal of Molecular Sciences, 2017, 18, 1968.	1.8	12
34	Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma. Neuro-Oncology, 2019, 21, 222-233.	0.6	12
35	Recapitulated Crosstalk between Cerebral Metastatic Lung Cancer Cells and Brain Perivascular Tumor Microenvironment in a Microfluidic Coâ€Culture Chip. Advanced Science, 2022, 9, .	5.6	12
36	Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer. Scientific Reports, 2020, 10, 4904.	1.6	10

#	Article	IF	Citations
37	Involvement of DDX6 gene in radio- and chemoresistance in glioblastoma. International Journal of Oncology, 2016, 48, 1053-1062.	1.4	9
38	Ethnic delineation of primary glioblastoma genome. Cancer Medicine, 2020, 9, 7352-7359.	1.3	6
39	Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma. Cancer Medicine, 2018, 7, 1774-1783.	1.3	5
40	Systematic Evaluation of Gastric Tumor Cell Index and Two-Drug Combination Therapy via 3-Dimensional High-Throughput Drug Screening. Frontiers in Oncology, 2019, 9, 1327.	1.3	5
41	Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. Gynecologic Oncology, 2022, 165, 270-280.	0.6	5
42	Antitumor activity, pharmacokinetics, tumor-homing effect, and hepatotoxicity of a species cross-reactive c-Met antibody. Biochemical and Biophysical Research Communications, 2017, 494, 409-415.	1.0	3
43	Somatic genomic landscape of East Asian epithelial ovarian carcinoma and its clinical implications from prospective clinical sequencing: A Korean Gynecologic Oncology Group study (<scp>KGOG</scp>) Tj ETQq1 1 0.784314 rgBT /Ove	2.3	4
44	Pharmacokinetics, Biodistribution, and Toxicity Evaluation of Anti-SEMA3A (F11) in In Vivo Models. Anticancer Research, 2018, 38, 2803-2810.	0.5	2
45	Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells. Stem Cell Reviews and Reports, 2021, , 1.	1.7	1
46	GENE-12. ANALYSIS OF FAILURE PATTERNS IN MALIGNANT GLIOMA: EXPLORING THE GENETIC LANDSCAPE OF PATTERN OF FAILURE. Neuro-Oncology, 2019, 21, vi100-vi100.	0.6	0